The Lancet Haematology· Haiyan He, Jingjing Shang, Yafei Wang, Zhongjun Xia, Fangbing Zhu, Yanli Yang, Baijun Fang, Wenming Chen, Bing Chen, Zhen Cai, Hui Zhou, Yajun Li, Hong Liu, Lijuan Chen, Yan Liu, Zhongxia Huang, Pengyun Zeng, Jie Jin, Yan Li, Jianqing Mi, Zeping Zhou, Sujun Gao, Yaming Xi, Qingming Wang, Chunkang Chang, Xin Du, Shang-Yi Huang, Hao-Yuan Wang, Po-Shen Ko, Zonghong Shao, Jun Luo, Shunqing Wang, Jinwen Huang, Mingshen Dai, Tonghua Yang, Rong Zhan, Bin Liang, Ming-Chung Wang, Suijing Wu, Liye Zhong, Yongqiang Wei, Hongxiang Wang, Huijing Wu, Juan Li, Chieh-Lin Teng, Yuan Meng, Minfang Wu, Ping Yang, Xi Chen, Andrew X Zhu, Weijun Fu, Depei Wu, Chengcheng Fu·· 2026-10-01精选AI 评分83
Felzartamab联合来那替尼与地塞米松对比来那替尼与地塞米松治疗复发难治性多发性骨髓瘤:一项随机3期试验
[Articles] Felzartamab plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial
AI 导读
一项开放、平行对照的随机3期试验显示,Felzartamab联合来那替尼与地塞米松在复发难治性多发性骨髓瘤患者中显著延长了无进展生存期,较单用来那替尼与地塞米松方案更具优势。
推荐理由
原文给出了III期随机试验中主要终点PFS的对比结论,可用于评估该方案在特定患者群体中的疗效证据。
来源:The Lancet Haematology · thelancet.com